IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the IRX-2 regimen and Durvalumab, will have a
tolerable safety profile and will increase the intratumoral immune profile compared with the
pretreatment tumors.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute